Friday, 22 Mar 2019

You are here

Update on Immune Checkpoint Inhibitor Toxicity

JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several.  ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.

ICIs block cytotoxic T lymphocyte antigen 4 (CTLA-4; ie, ipilimumab), programmed death 1 (PD-1; ie, nivolumab, pembrolizumab), or programmed death ligand 1 (PD-L1; ie, atezolizumab, avelumab, durvalumab).

Immune checkpoints on T cells normally prevent autoimmunity by inhibiting dendritic cell-mediated T-cell activation (CTLA-4) or by inducing T-cell exhaustion at sites of inflammation (PD-1/PD-L1).  By removing inhibition of T-cell function, ICIs facilitate T-cell–mediated actions on tumors but in doing so they may promote T-cell autoimmune activity against host tissues. As such ICIs have been associated with numerous examples of organ-specific inflammation, and autoimmune events described within this  review.

Autoimmune AEs associated with anti–CTLA-4 regimens occur earlier, more frequently, and are more severe than autoimmune AEs associated with anti–PD-1/PD-L1 monotherapy.  Thus will AE arise acutely, they may respond to steroids within 1 to 7 days. Low-dose steroids (prednisone, 0.5 mg/kg) are generally used for mild AEs and high dose glucocorticoids (1-2 mg/kg) for more severe AEs. AEs may reappear after discontinuation of steroids in approximately 10% of patients, and cause hospitalization in 5% (anti-PD-1 monotherapy) to 36% (combination anti-CTLA-4/anti-PD-1) of patients. Steroid nonresponders should be considered for second-line immunosuppression, such as infliximab or mycophenolate mofetil.

Common manifestations of immune-mediated adverse events with ICIs include:

  • Colitis: occurs 25% of patients treated with ipilimumab and < 5% of patients treated with anti–PD-1/PD-L1 monotherapy. Colitis may be life-threatening or mild watery diarrhea. Colonoscopy, steroids and even biologic therapies may be necessary.
  • Pneumonitis: also potentially life-threatening, may be seen in 2% to 5% of patients treated with ICIs. Symptoms may prompt evaluation with computed tomographic imaging - revealing ground glass opacities and/or interstitial thickening, High-dose steroids (1-2 mg/kg/d) are indicated in symptomatic patients.
  • Cutaneous: up to 30% of patients treated with ICIs and include pruritus, acneiform rash, and toxic epidermal necrolysis. Blisters or mucosal involvement are rare (<1%) but suggest a bullous disorder or Stevens-Johnson syndrome and require prompt dermatology evaluation and high-dose steroids.
  • Endocrine Dysfunction: Hypophysitis (pituitary inflammation) is one of the more common AE with anti–CTLA-4 therapy (up to 10% incidence), but is rarely seen with other ICIs. Patients with hypophysitis present with signs and symptoms of adrenal insufficiency, such as hypotension and fatigue and headaches. Hypothyroidism occurs in up to 20% of treated patients, is often preceded by asymptomatic inflammatory thyroiditis, and requires thyroid hormone replacement. Hyperthyroidism is less common, may be transient and followed by hypothyroidism.
  • Hepatitis: seen in 1% of patients prescribed anti‐PD1/PD‐L1 agents and 10% of patients prescribed anti-CTLA-4 agents.
  • Myocarditis and myositis: inflammatory myocarditis occurs in less than 1% of patients treated with ICIs, often presents with concurrent skeletal muscle myositis, may be fulminant or smoldering in nature, and has a 20% to 50% risk of death. Patients with myocarditis present with fatigue, shortness of breath, chest discomfort, and troponin elevations and conduction disturbances.
  • Neurotoxicity: tends to be rare (<1% of patients treated with ICIs) but severe neurotoxicities include Guillain-Barré syndrome, myasthenia gravis, and encephalitis.9 Guillain-Barré syndrome and myasthenia gravis require prompt disease-specific management 

 

 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Best of 2018: The Safety of Paternal Exposure to DMARDs and Biologics

Pregnancy and drug safety is a complex issue, often with limited information about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.

A systematic review examined the effect of disease modifying anti-rheumatic drugs (DMARDs) on male fertility and if peri-conception (within 3 months) paternal exposure was detrimental to fetal outcomes.

Best of 2018: Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).

CDC Top 15 Most Common Opioid Overdose Drugs

The Dec. 12 issue of the National Vital Statistics Reports from the U.S. Centers for Disease Control and Prevention reports that the most commonly abused drugs causing drug overdose deaths (between 2011-2016) include fentanyl, heroin, oxycodone, and cocaine.

Trazodone High Risk of Falls and Fractures

The CMAJ (Canadian Medical Association Journal) has reported that trazadone use in the elderly may be associated with a risk of falls and major fractures. 

Using claims data from ICES, researchers compared 6588 seniors given trazadone to 2875 receiving another atypical antipsychotic.

Musculoskeletal Events with Statin Use

Analysis of the FDA Adverse Event Reporting System data examined the association between statins' musculoskeletal adverse events (MAEs).

Review of the data shows that atorvastatin and rosuvastatin (with strong low‐density lipoprotein cholesterol‐lowering effects) had a higher risk and a faster onset of MAEs when compared with simvastatin.

They could not detect whether concomitant drugs shifted the onset timing of MAEs.